Arbutus Announces Appointment of Daniel Burgess to Board of Directors
March 23 2017 - 4:30PM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that the Company has appointed Daniel Burgess to the
Board of Directors and Audit Committee effective immediately.
Mr. Burgess has more than 25 years of executive
level operating experience in biotech companies, including
substantial experience in the anti-infective field. He is
currently a Venture Partner at SV Life Sciences, is Chairman of the
Board of Nabriva Therapeutics (NASDAQ:NBRV) and is on the board of
Cidara Therapeutics (NASDAQ:CDTX) as well as several private
biotechnology companies. In addition, he is Chairman of
Biocom, the life science industry organization of California that
represents more than 800 member companies. Prior to his current
roles, Mr. Burgess was President of Rempex Pharmaceuticals, a
company he co-founded in 2011 and subsequently sold to The
Medicines Company in December 2013. Prior to Rempex, Mr. Burgess
was President and Chief Executive Officer of Mpex Pharmaceuticals,
Inc., which was acquired by Aptalis Pharma Inc. (now Allergan) in
2011. Previously, Mr. Burgess was Chief Operating Officer and Chief
Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden
Pharmaceuticals, Inc. Prior to Hollis-Eden, Mr. Burgess spent ten
years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical
Industries Limited) where he held a variety of executive level
positions with responsibility for overall finance for the company
as well as a number of different operating units. Mr. Burgess holds
a B.A. in economics from Stanford University and an M.B.A. from
Harvard Business School.
About Arbutus
Arbutus Biopharma Corporation is a
biopharmaceutical company dedicated to discovering, developing and
commercializing a cure for patients suffering from chronic HBV
infection. Arbutus is headquartered in Vancouver, BC, and has
facilities in Doylestown, PA. For more information, visit
www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: acutler@arbutusbio.com
Media
David Schull
Russo Partners
Phone: 858.717.2310
Email: david.schull@russopartnersllc.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024